Benzimidazole ligands display a wide range of pharmacological activities, and are used for therapeutic purposes concerning many diseases, such as antifungal, antibacterial, antihelmintic, antiallergic, antineoplastic, local analgesic, antihistaminic, hypotensive, vasodialator, spamolytic and antiulser activities. 1 In addition to their biological importance, these ligands are strongly coordinated and form stable complexes with various transition metals. Transition-metal complexes of benzimidazols are progressively being used to model important bioinorganic systems. 2 Experience has shown that compounds with biological activity are often derived from heterocyclic structures that appear frequently in natural products. 3 On the other hand, metal complexes of biologically important ligands are sometimes more effective than a free ligand. 4 The aim of this study was to synthesize and elucidate the crystal structure of a new benzimidazole cobalt complex, and then to compare the results with our previous studies involving related benzimidazole metal complexes. 5 A mixture of 1-pentylbenzimidazole (0.5 g; 2.67 mmol) and cobalt dichloride (0.17 g; 1.33 mmol) in ethanol (10 ml) was heated under reflux for 3 h. All volatiles were removed in vacuo (0.02 mmHg; 1 mmHg=133.322 Pa). The crude product was crystallized from a DMF/EtOH (2:1) mixture upon cooling at 243 K (yield: 0.57 g, 85%; m.p. 411 -412 K). The crystal and molecular structures of the title compound were elucidated by single-crystal X-ray diffraction.
Benzimidazole ligands display a wide range of pharmacological activities, and are used for therapeutic purposes concerning many diseases, such as antifungal, antibacterial, antihelmintic, antiallergic, antineoplastic, local analgesic, antihistaminic, hypotensive, vasodialator, spamolytic and antiulser activities. 1 In addition to their biological importance, these ligands are strongly coordinated and form stable complexes with various transition metals. Transition-metal complexes of benzimidazols are progressively being used to model important bioinorganic systems. 2 Experience has shown that compounds with biological activity are often derived from heterocyclic structures that appear frequently in natural products. 3 On the other hand, metal complexes of biologically important ligands are sometimes more effective than a free ligand. 4 The aim of this study was to synthesize and elucidate the crystal structure of a new benzimidazole cobalt complex, and then to compare the results with our previous studies involving related benzimidazole metal complexes. 5 A mixture of 1-pentylbenzimidazole (0.5 g; 2.67 mmol) and cobalt dichloride (0.17 g; 1.33 mmol) in ethanol (10 ml) was heated under reflux for 3 h. All volatiles were removed in vacuo (0.02 mmHg; 1 mmHg=133.322 Pa). The crude product was crystallized from a DMF/EtOH (2:1) mixture upon cooling at 243 K (yield: 0.57 g, 85%; m.p. 411 -412 K). The crystal and molecular structures of the title compound were elucidated by single-crystal X-ray diffraction.
A summary of the crystallographic information is given in Table 1 . The data were collected on a Rigaku R-AXIS RAPID-S diffractometer with an imaging-plate detector diffractometer using graphite-monochromated Mo Kα radiation with the ω-scan mode.
The collected data were reduced by using the CrystalClear program, and an absorption correction using the refdelf procedure in the XABS2 program was applied (cubic fit to sin(theta)/lambda-24 parameters). The title compound was solved by direct methods and refined by a full-matrix leastsquares method on F 2 . All H atoms were located geometrically and constrained to ride on their parent atoms in the range The Co atom in the title compound is coordinated tetrahedrally by two Cl atoms and two N atoms (Fig. 2) . The Cl2N2 donor set defines a distorted tetrahedron, with angles ranging from 104.84(9) to 114.52(5)˚. The average Co-N bond length of 2.012(3)Å may be compared with the reported average values of 2.008(2)Å for dichlorobis[1-(2-ethoxyethyl)-1Hbenzimidazole-κN 3 ]cobalt(II). 5 The Co-Cl bond lengths of 2.2559(12) and 2.2749(10)Å in the title compound are nearly equal to the corresponding lengths reported for dichlorobis[1-(2-ethoxyethyl)-1H-benzimidazole-κN 3 ]cobalt(II), viz. 2.2423(6) and 2.5616(6)Å. 5 The N1/N2/C1-C7 and N3/N4/C13-C19 benzimidazole systems are almost planar, with the maximum deviations of atoms C1, C6 and C7 (first system), and atoms C13, C18 and C19 (second system) from the mean planes, of 0.035(4), 0.029(4) and -0.075(5)Å (first system), and 0.026(5), 0.031 (5) and -0.030(5)Å (second system), respectively. The dihedral angle between the least-squares planes through the two benzimidazole ring systems is 66.23(15)˚. In the crystal structure of the title compound, individual molecules are loosely associated into pairs via C-H·Cl hydrogen-bonding interactions ( Table 3 ). Table 2 Selected bond distances (Å) and angles (˚) Table 3 Hydrogen-bond geometry (Å,˚) Symmetry code: (i) 4/3-x + y, 2/3-x, -1/3 + z.
